Significant shareholder

RNS Number : 3915C

Open Orphan PLC

07 February 2020

 

7 February 2020

Open Orphan plc

("Open Orphan" or the "Company")

Significant shareholder

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services,  has been advised today that, as of 31 January 2020, Jupiter Asset Management Limited's ("Jupiter") interest in the Ordinary Shares of 0.1p in the Company fell below 3% of the total voting rights of the Company. Accordingly, Jupiter have ceased to be a significant shareholder in the Company, as defined by the AIM Rules for Companies.

For further information please contact:

Open Orphan plc Cathal Friel, Executive Chairman               Trevor Phillips, Chief Executive Officer	[phone] [phone]
Arden Partners plc (Nominated Adviser and Joint Broker) John Llewellyn-Lloyd / Benjamin Cryer	[phone]
Davy (Euronext Growth Adviser and Joint Broker) Anthony Farrell	[phone]
Camarco (Financial PR)
Tom Huddart / Daniel Sherwen	[phone]

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools.  In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Corona virus in 2020 The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

 

END

 

 

MSCUPUUCPUPUGAM